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Abstract 
Background: Patients with intestinal Behçet’s disease (BD) frequently undergo intestinal resections, which signifi-
cantly affects postoperative morbidity and mortality. The aim of this study was to identify the association between 
C-reactive protein (CRP) levels and postoperative outcomes in patients with intestinal BD who underwent surgical 
bowel resection.
Methods: Patients who were diagnosed with intestinal BD and underwent intestinal surgery due to BD at Severance 
Hospital between November 2005 and April 2018 were retrospectively investigated. Clinical relapse was defined as 
a disease activity index of BD (DAIBD) > 40, existence of newly added medications, re-hospitalization, or re-operation 
related to intestinal BD. The relationship between CRP level and postoperative outcomes was analyzed, and a receiver 
operating characteristic (ROC) curve was drawn to specify a cut-off value.
Results:   Ninety patients with intestinal BD were included. Among them, 44 were male (48.9%), and the median age 
at diagnosis was 38 years (range, 11–69 years). The median total disease follow-up duration was 130 months (range, 
3–460 months). Forty patients (44.4%) underwent laparoscopic surgery. A higher CRP level immediately after surgery 
was significantly associated with postoperative complications (OR 1.01, 95% CI 1.004–1.018, p < 0.01), re-operation 
(hazard ratio [HR] 1.01, 95% CI 1.005–1.020, p < 0.01), and re-admission (HR 1.01, 95% CI 1.006–1.017 p < 0.01). The ROC 
curve showed that CRP predicts the risk of postoperative complications (p < 0.01) at a cut-off value of 41.9% with a 
sensitivity of 60.0% and specificity of 67.7%.
Conclusions: Postoperative CRP levels in patients with intestinal BD undergoing surgical resection were associated 
with postoperative outcomes.
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Background
Behçet’s disease (BD) is caused by chronic vascular 
inflammation in multiple organs and is characterized 
by oral and genital ulcers, uveitis, arthritis, skin rash, 
vasculitis, neurologic manifestations, and/or gastroin-
testinal inflammation [1, 2]. The etiology of BD remains 
unclear, but several genetic factors and human leuko-
cyte antigen (HLA)-B*51 are well known to be associated 
with BD development [3–5]. Environmental factors and 
Open Access
*Correspondence:  nagase96@yuhs.ac; geniushee@yuhs.ac
†Eun Ae Kang and Jung Won Park contributed equally to this work as the 
first authors
†Min Soo Cho and Jae Hee Cheon contributed equally to this work
1 Gastroenterology and Department of Internal Medicine, Yonsei 
University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 03722, Republic of Korea
2 Division of Colon and Rectal Surgery, Department of Surgery, Yonsei 
University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 03722, Republic of Korea
Page 2 of 9Kang et al. BMC Gastroenterol          (2021) 21:362 
immunological dysregulation also play a role in patho-
genesis. BD is more prevalent in the Middle East and 
East Asia, including South Korea [6, 7]. There is no single 
diagnostic test for BD; however, the following diagnos-
tic criteria for BD are commonly used: presence of oral 
ulcers and any two out of genital ulcers, eye lesions, skin 
lesions, and positive pathergy test [8].
BD involvement in the gastrointestinal tract, so called 
“intestinal BD,” is characterized by typical deep ulcerative 
lesions in the ileocecal valve area based on colonoscopy. 
Patients with intestinal BD may have significant gastro-
intestinal symptoms, such as abdominal pain, diarrhea, 
and gastrointestinal bleeding, but some patients are 
asymptomatic with a quiescent disease status. Intestinal 
BD is rare but is more prevalent in East Asia, including 
Korea and Japan, than in other regions [9]. Intestinal BD 
may cause severe complications, such as perforation or 
massive gastrointestinal bleeding, requiring intestinal 
resection. Intestinal BD is significantly associated with 
morbidity and mortality in patients with BD.
Intestinal BD can reoccur after intestinal surgery with 
a chronic, relapsing disease course and may require anti-
tumor necrosis factor (TNF) therapy or re-operation. 
Postoperative outcomes, including complications and 
relapse, are critical in the prognosis of BD [10, 11]. Early 
detection of complications and their appropriate man-
agement can improve patient prognosis. Therefore, it is 
important to promptly assess the possibility of poor out-
comes after surgery for intestinal BD. C-reactive protein 
(CRP) is a representative serological marker of inflam-
mation. However, there is still little research on whether 
postoperative CRP levels and the degree of CRP reduc-
tion are associated with postoperative prognosis, par-
ticularly in intestinal BD [12, 13]. Herein, we aimed to 
identify the association between CRP levels and postop-




This study was a retrospective observational study 
that enrolled patients with intestinal BD who under-
went intestinal surgery due to complications or refrac-
toriness of intestinal BD in a single tertiary hospital 
between November 2005 and April 2018. Electronic 
medical records were retrospectively reviewed. Patients 
with intestinal BD who underwent surgery unrelated to 
intestinal BD were excluded. Clinical factors, including 
age at diagnosis, sex, prior abdominal surgical history, 
and history of perioperative medical treatment, were 
investigated. Disease duration, intestinal symptoms, 
and disease activity index of BD (DAIBD) prior to sur-
gery were also evaluated. Laboratory findings, such as 
CRP, albumin, and hemoglobin levels, within 5 days 
after surgery were also investigated.
Definitions and subtypes of intestinal BD
Intestinal BD was diagnosed if patients with systemic 
BD had ulcerations in the gastrointestinal tract, espe-
cially in the ileocecal area. Clinical symptoms, radio-
logic, endoscopic, and histologic findings based on 
the diagnostic criteria for BD were used for diagnosis 
[14–16]. If patients had typical intestinal ulcers in the 
ileocecal area and was also diagnosed as having sys-
temic BD, these cases were regarded as “definite” intes-
tinal BD. If patients had typical intestinal ulcers but 
only had oral ulcers or had atypical intestinal ulcers but 
was diagnosed as having systemic BD, it was defined 
as “probable” intestinal BD. If patients had only typi-
cal intestinal ulcers without systemic manifestations of 
BD or had atypical intestinal ulcers and oral ulcers only, 
we defined it as “suspected” intestinal BD [16]. Typical 
lesions were defined as deep, oval-shaped, and well-
demarcated ulcers less than five in the ileocecal region 
[16, 17].
Outcomes
Postoperative outcomes, including the presence of post-
operative complications within one month and clini-
cal relapse after intestinal surgery, were investigated. 
Postoperative complications included anastomotic leak, 
intra-abdominal abscess, fistula, wound infection, bleed-
ing, perforation, other infections, and wound dehiscence. 
Clinical relapse was defined as an increase in DAIBD 
to > 40, newly added medications due to aggravation of 
intestinal BD, re-admission due to symptomatic aggra-
vations, or cases of re-operation related to intestinal BD 
[18]. DAIBD consists of a general sense of well-being for 
a week (0 to 40, add 10 points as severity increases), pres-
ence of fever (if yes, add 10 points), abdominal mass (if 
yes, add 10 points), abdominal tenderness (if yes, add 10 
or 20 points according to severity), extra-intestinal mani-
festations (add 5 points per item; oral ulcer, genital ulcer, 
eye lesion, skin lesion, arthralgia; add 15 points for vas-
cular or central nervous system involvement), abdomi-
nal pain for one week (0 to 80, add 20 points according 
to severity), intestinal complications (add 10 points per 
item; fistula, perforation, abscess, or intestinal obstruc-
tion), and liquid stool in a week (add 10 points) [19].
Serum CRP levels (mg/L) were measured within five 
days after surgery. Follow-up CRP levels before discharge 
were measured repeatedly. We investigated the hazard 
ratio (HR) of CRP levels for postoperative outcomes in 
patients with intestinal BD.
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Ethical considerations
The need for informed consent was waived due to the 
retrospective nature of the observational study.  The 
study protocol was approved by the institutional review 
board of Severance Hospital. Personal information data 
were anonymized. All authors had access to the data of 
this study and approved the final version of the manu-
script (institutional review board number: 4-2021-0078).
Statistical analysis
Categorical variables were analyzed using the χ2 test, 
and continuous variables were analyzed using Student’s 
t-test. The relationship between CRP level and postop-
erative outcomes of intestinal BD was measured using 
logistic regression analysis. Other clinical factors were 
identified by multivariate analysis using Cox proportional 
hazard regression model. Furthermore, an area under 
the receiver operating characteristic curve was drawn to 
evaluate the accuracy of the results and to specify a cut-
off value. Statistical significance was set at p < 0.05. All 
statistical analyses were performed using SPSS software 
version 25.0 for Windows (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of study population
A total of 124 patients with intestinal BD were screened. 
Patients whose diagnosis was incorrectly recorded in 
medical records were excluded (n = 28), and patients 
whose diagnosis was changed to another inflammatory 
disease during follow-up were excluded (n = 3). Patients 
who underwent surgery for reasons other than BD were 
also excluded from the final analysis (n = 3). Finally, 90 
patients with BD who underwent intestinal surgery were 
investigated (Fig. 1). Forty-four (48.9%) had a median age 
of 38 years (range, 11–69 years). Median disease follow-
up duration was 11.8 years (0.3–38.4 years). Detailed 
information on the use of perioperative medications, 
including 5-aminosalicylic acids (5-ASA), immunomod-
ulators (azathioprine, 6-mercaptopurine, methotrex-
ate), colchicine, corticosteroids, and anti-TNF agents, 
are shown in Table 1. A laparoscopic approach was per-
formed in 40 patients (44.4%). Emergent surgery was 
performed in 13 cases, mainly due to peritonitis and per-
foration. The CRP level was measured at a median of 2 
(1–4) days after surgery. The number of patients and CRP 
levels on each day for which CRP was measured after 
surgery were shown in Additional file 1:  Table S1.
Postoperative complications and clinical relapse 
after intestinal surgery in patients with intestinal BD
Postoperative complications within one month after sur-
gery occurred in 25 patients (27.8%), and events occurred 
in a total of 32 patients (35.6%). Postoperative complica-
tions included anastomotic leak, abscess formation, fis-
tula, wound infection, ileus, bleeding, perforation, and 
other infections. Clinical relapse occurred in 52 patients 
(57.8%), and the total number of events was 78 (Table 2). 
Surgical method, such as open surgery or laparoscopic 
surgery, did not affect the clinical relapse (p = 0.42), re-
operation (p = 0.23), re-admission (p = 0.96), or post-
operative complications (p = 0.14) rates. Furthermore, 
whether surgery was emergent or elective also did not 
affect outcomes (clinical relapse, p = 0.13; postoperative 
complications, p = 0.11).
Risk factors for postoperative outcomes, 
including postoperative CRP levels
Mean CRP levels between patients with or without post-
operative complications differed significantly (99.44 mg/L 
vs. 41.95 mg/L, p = 0.01). Patients who were readmitted 
after surgery had higher CRP levels than those who were 
not (73.40 mg/L vs. 41.72 mg/L, p = 0.03).
Risk factors for postoperative outcomes in patients 
with BD were analyzed using Cox proportional hazard 
regression analysis. The median time to relapse was 
49 months (interquartile range, 13.3–115.3). A higher 
postoperative CRP level was an independent risk fac-
tor for postoperative complications and clinical relapse, 
including re-operation and re-admission (Table  3). 
The association between CRP levels and postoperative 
outcomes was statistically significant when adjusted 
for age, sex, and perioperative use of medications. A 
subgroup analysis that included only patients with 
CRP levels within 4 days after surgery showed similar 
results in terms of their association with postopera-
tive outcomes; postoperative complications (HR 1.01 
(1.002–1.016), p = 0.02), readmission (HR 1.01 (1.001–
1.013), p = 0.02), and reoperation (HR 1.01 (1.001–
1.017), p = 0.03). Anti-TNF agents tended to lower 
Fig. 1 Patients who met inclusion criteria
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postoperative complications and relapses but were not 
statistically significant. Corticosteroid use was associ-
ated with postoperative complications (HR 4.36 (1.21–
15.68), p = 0.02) and re-operation (HR 3.31 (1.15–9.56), 
p = 0.03). Typical volcanic intestinal ulcers and intes-
tinal fistulas were related to clinical relapse, especially 
re-admission (Additional file 1: Table S2).
Predictive power and cut‑off value of CRP 
for postoperative outcomes in intestinal BD
We evaluated the predictive power of CRP levels for 
postoperative outcomes in patients with intestinal BD. 
As shown in Table  4; Fig.  2, the area under the curve 
(AUC) of postoperative complications was 69.9%, and 
the sensitivity was 60.0%. The AUC of clinical relapse, 
including re-operation and re-admission, was 63.3%, 
and the sensitivity was 51.9%.
Discussion
  BD is a systemic vasculitis that involves several organs, 
including the mouth, eyes, skin, nervous system, and gas-
trointestinal tract. Intestinal BD is an important subtype 
of BD that can cause serious morbidity and poor quality 
of life in patients with BD. Intestinal BD is characterized 
by chronic and recurrent inflammation and deep ulcera-
tive lesions of the gastrointestinal tract, especially in the 
terminal ileum and ileocecal valve [20, 21]. Suspected 
intestinal BD was defined as having a typical intestinal 
ulcer with no systemic symptoms or an atypical intesti-
nal ulcer with only oral ulcers. Many gastroenterologists 
consider intestinal BD when intestinal ulcers are typical, 
even if systemic symptoms are not completely satisfac-
tory for systemic BD [22–24]. Since we have focused on 
the postoperative outcome of intestinal BD rather than 
systemic BD, the probable and suspected cases of intesti-
nal BD should also be included in the analysis. Intestinal 
BD, similar to other inflammatory bowel diseases, such as 
Table 1 Baseline characteristics of study population
CRP C-reactive protein, n number, TNF tumor necrosis factor
Patient characteristics Patients (n = 90)
Male (number, %) 44 (48.9%)
Age at diagnosis (median, range; years) 38 (11–69)
Disease follow-up period (median, range; years) 11.8 (0.3–38.4)
Duration between diagnosis and surgery (median, range; months) 23 (0–217)
Subtype of disease
 Definite 68 (75.6%)
 Probable 2 (2.2%)
 Suspected 20 (22.2%)
Oral ulcers 66 (73.3%)
Genital ulcers 31 (34.4%)
Skin manifestations 30 (33.3%)
Typical intestinal ulcers 86 (95.6%)
Fistula / abscess 11 (12.2%)/4 (4.4%)
Perioperative medical treatment (number; %)
 5-aminosalicylic acids 86 (95.6%)
 Immunomodulator 53 (58.9%)
  Azathioprine 43 (47.8%)
  6-Mercaptopurine 3 (3.3%)
  Methotrexate 7 (7.8%)
 Colchicine 45 (50.0%)
 Corticosteroids 74 (82.2%)
 Anti-TNF antagonist 12 (13.3%)
Surgical technique (number; %)
 Laparoscopy 40 (44.4%)
 Open 50 (55.6%)
Emergent surgery 13 (14.4%)
CRP (mg/L) 57.0 ± 71.2
Day of CRP measurement after surgery (median, interquartile range; days) 2 (1–4)
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CD and ulcerative colitis, is usually treated with 5-ASA, 
corticosteroids, immunomodulators, and/or anti-TNF 
agents [25–27]. However, intestinal BD may reoccur or 
worsen due to refractoriness or loss of response to medi-
cations and may require surgical intervention [2]. Few 
studies have examined the surgical outcomes of intesti-
nal BD; however, those studies that have been published 
showed that a large number of patients can experience 
recurrence after surgery and ultimately undergo stoma 
[11]. Patients with intestinal BD may experience post-
operative complications and recurrence more frequently 
than patients with other intestinal diseases, which neces-
sitates the development of an appropriate predictor of 
postoperative prognosis. Early recurrence can occur 
within one month after surgery. Therefore, high-risk 
groups must be promptly identified and appropriately 
treated.
The present study aimed to investigate the role of CRP 
as a predictive marker of postoperative complications 
and clinical relapse in intestinal BD. CRP levels can be 
elevated in patients with acute inflammation or infec-
tion. The relationship between postoperative CRP levels 
immediately (within 5 days) after surgery and postop-
erative outcomes was analyzed. According to public 
insurance standards, CRP levels cannot be frequently 
measured in Korea within 3 to 4 days. Therefore, the cri-
teria for postoperative CRP levels were defined within 5 
days due to clinical limitations in verifying CRP levels. 
The CRP level was measured at a median of one postop-
erative days, which did not differ significantly between 
patients. Our data demonstrated that the elevation of 
postoperative CRP levels was associated with a poorer 
prognosis for postoperative complications and recur-
rence. The association between CRP levels and poor 
postoperative outcomes was also statistically significant 
when we included only patients with CRP levels within 
Table 2 Postoperative complications and clinical relapse 
in patients with intestinal Behçet’s disease after undergoing 
intestinal surgery
*Cases in which disease activity is increased, only new drugs are added without 
surgery or hospitalization
DAIBD disease activity index of intestinal Behçet’s disease
Number (%)
Postoperative complications
Total (events/patients, number) 32/25 (27.8%)
 Anastomosis leak 8 (25.0%)
 Intra-abdominal abscess 6 (18.8%)
 Fistula 5 (15.6%)
 Wound infection 5 (15.6%)
 Ileus 2 (6.2%)
 Bleeding 3 (9.4%)
 Perforation 2 (6.2%)
 Other infection 1 (3.1%)
 Wound dehiscence 0 (0.0%)
Clinical relapse
Total (events/patients, number) 76/52 (57.8%)
 DAIBD > 40 or additional medications  needed* 5 (6.6%)
 Re-operation 24 (31.6%)
 Re-admission 47 (61.8%)
Table 3 Association of postoperative C-reactive protein levels with postoperative complications and clinical relapse in patients with 
intestinal Behçet’s disease
*Adjustment for age at diagnosis, sex, perioperative medication use including anti-TNF agents, immunomodulators, and corticosteroids
CI confidence interval, HR hazard ratio
Crude HR (95% CI) p‑value *Adjusted HR (95% CI) p‑value
Postoperative complication 1.01 (1.005–1.016) < 0.01 1.01 (1.004–1.018) 0.01
Clinical relapse 1.01 (1.006–1.013) < 0.01 1.01 (1.005–1.016) < 0.01
Re-operation 1.01 (1.006–1.018) < 0.01 1.01 (1.005–1.020) < 0.01
Re-admission 1.01 (1.006–1.015) < 0.01 1.01 (1.006–1.017) < 0.01
Table 4 Area under the curve for postoperative complications and clinical relapse
AUC area under the curve
AUC (%) p‑value Threshold (mg/L) Sensitivity (%) Specificity (%)
Postoperative complications 69.9 0.004 41.9 60.0 67.7
Clinical relapse 63.3 0.036 28.6 51.9 60.0
Re-operation 60.6 0.067 28.2 44.4 50.0
Re-admission 61.4 0.067 41.9 50.0 70.7
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4 days after surgery. However, since CRP levels were low 
on day 5 after surgery, it is recommended to measure 
CRP levels early to predict the prognosis after surgery. 
Emergency surgery and the use of drugs, such as anti-
TNF agents, did not affect these results and confirmed 
that CRP is an independent prognostic factor for post-
operative outcomes in intestinal BD. According to Addi-
tional file 1: Tables S2, corticosteroid use was associated 
with postoperative complications and re-operation. Typi-
cal volcanic intestinal ulcers and intestinal fistulas were 
related to clinical relapse, especially re-admission. Typi-
cal bowel lesions or fistulas were inversely correlated with 
clinical recurrence. This indicated that typical lesions can 
certainly be treated with surgery.
According to a Japanese study on BD, a large number 
of BD patients experience surgery and recurrence within 
2 years, and the cumulative recurrence rate reaches 
30–75%. In Korea, the cumulative recurrence rate within 
2 years and 5 years after surgery is 12.5% and 22.2–31%, 
respectively [12]. These findings support our findings. In 
addition, long-term comparisons of patients with intesti-
nal BD who had surgery or not have shown that patients 
with ileal and ocular lesions had a higher surgical emer-
gency and experienced frequent relapses after surgery 
[10].
Long-term clinical outcomes and prognostic factors 
after intestinal surgery have been studied [28, 29]. The 
presence of deep ulcers, fistula, abscess, leakage of the 
anastomosis site, and postoperative use of corticosteroids 
have been suggested to be risk factors [10, 30, 31]. CRP 
levels over 4.4 mg/dL were a risk factor for relapse [12]. 
Mucosal healing can reduce the risk of surgery and recur-
rence of intestinal BD [32]. A previous study showed that 
early preemptive surgery had a better prognosis than sur-
gery due to disease aggravation or complications [33]. 
The postoperative use of azathioprine can reduce clinical 
relapse [34]. Anti-TNF agents can also improve the clini-
cal course of intestinal BD compared with the use of cor-
ticosteroids [25, 35]. Furthermore, emergent surgery and 
elevation of postoperative erythrocyte sedimentation rate 
were prognostic factors for re-operation within 6 months 
in intestinal BD [36]. However, there are no studies on 
the predictors of early recurrence or complications after 
surgery for intestinal BD. To date, there is little evidence 
of clear factors or biomarkers for predicting postopera-
tive prognosis in intestinal BD. To the best of our knowl-
edge, this is the first study to investigate the role of CRP 
in postoperative complications and recurrence in intesti-
nal BD.
  Several studies have analyzed predictors of recur-
rence and postoperative complications in CD. A pro-
spective cohort study reported that male sex, cigarette 
smoking, and history of intestinal resection were risk 
factors for recurrence of CD [37]. Disease behav-
ior, such as penetrating or structuring type, is a well-
established risk factor for postoperative recurrence 
[38–40]. Perianal disease is also accepted as a risk fac-
tor for recurrence and poor prognosis [41]. Interest-
ingly, a higher CRP level was shown to be a risk factor 
for poor prognosis of CD [42–44], and CRP level was 
reported to be associated with early postoperative sur-
gical outcomes, which is consistent with our findings 
[45]. However, surgical predictors such as the type of 
Fig. 2 Area under the curve (AUC) of predictive value of CRP level 
for postoperative complications (a) and clinical relapse (b) in patients 
with intestinal BD
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anastomosis, surgical methods, and histological find-
ings of surgical margins were not associated with post-
operative outcomes. Intestinal resection for CD or 
intestinal BD is not curative because of the chronic and 
relapsing disease course of the disease. Therefore, post-
operative complications and recurrence should be care-
fully monitored to improve the prognosis.
Emergent surgery is expected to have a higher risk, 
but there was no significant effect due to the small 
number of patients in this study. However, elective 
preemptive surgery may be more helpful in reducing 
postoperative complications than emergency surgery, 
and patients with elevated CRP levels after surgery 
should be carefully monitored for the occurrence of 
complications and relapse. Since CRP is an easily meas-
urable marker, it has high clinical utility. However, 
several clinical situations need to be considered. In 
particular, since the predictability of long-term clini-
cal recurrence is low, an individualized follow-up plan 
should be determined considering several known prog-
nostic factors.
This study has several limitations. The predictive 
power and sensitivity of postoperative CRP levels were 
not high, probably because of the small sample size. 
CRP may be associated with other systemic infections 
or residual inflammation after surgery. Therefore, there 
is a continuing need for research on specific markers 
to predict the postoperative outcome of intestinal BD. 
Selection bias may exist because of the retrospective 
nature of the study. However, CRP may be a candidate 
predictive marker when referring to several previous 
studies and considering the high likelihood of recur-
rence and re-operation after the first surgery for intes-
tinal BD. The usefulness of CRP as a surrogate marker 
has been reported in previous studies [46]. Our results 
appear to be meaningful, since we adjusted for emer-
gency surgery and perioperative medications. Postop-
erative CRP levels were defined within 5 days as there 
were no previous studies that discussed the best time 
to measure postoperative CRP to predict postopera-
tive outcomes. CRP levels on day 5 were relatively low 
compared with those on days 1–4. However, similar 
results and statistical significance were obtained when 
patients were included within 5 and 4 days. Therefore, 
we included all patients with CRP levels within 5 days, 
and future studies are needed to find a meaningfully 
optimal time for postoperative CRP measurement. 
Since this was a retrospective study, we have limited 
data on fecal calprotectin. Fecal calprotectin can be a 
surrogate marker of remission in patients with intesti-
nal BD [47]. Future prospective studies are needed to 
confirm the usefulness of CRP in predicting postopera-
tive outcomes.
Conclusions
Despite these limitations, this is the first study to focus 
on postoperative CRP levels, short-term postopera-
tive complications, and clinical relapse. A few studies 
have reported the role of CRP at diagnosis in determin-
ing long-term clinical outcomes and prognosis. Postop-
erative CRP levels in intestinal BD patients undergoing 
intestinal surgery are also correlated with early postop-
erative outcomes. Regardless of whether it was an emer-
gency surgery or what medications were used before 
surgery, physicians should measure CRP levels after sur-
gery, select the appropriate medications, and perform a 
careful follow-up taking into account the risk of compli-
cations and recurrence. CRP is relatively inexpensive and 
easily measured in the clinical settings. It is meaningful 
to consider more complications and risk of early recur-
rence in patients with high postoperative CRP through 
this study. If a patient’s CRP is high after surgery, it can be 
more carefully monitored and prepared for rapid action.
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